Invest in Cannabinoid-Based Medicines

Emerald Health Pharmaceuticals “EHP”, is a clinical stage drug development company focused on treating life-threatening diseases through cannabinoid science. The company has two families of new therapies, which are derivatives of cannabidiol (CBD) and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. EHP is headquartered in San Diego, California, and has R&D operations in Córdoba, Spain.

EHP is currently engaged in a Regulation A+ offering, which allows the company to accept direct investments from accredited and non-accredited investors. Please take a moment to review the offering circular. To access the subscription agreement please visit our website at www.investehp.com.

Deal Type                       Regulation A+, Tier 2

Issue Price                    $6 per share

Contact us:                    1.888.468.3471 or email us at invest@emeraldpharma.life

Learn more:                  www.investehp.com